

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 15280-2912

Assistant Commissioner for Patents
Washington, D.C. 20231

On 3/12/99

TOWNSEND and TOWNSEND and CREW LLP

By: Jennifer K. Hardin

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GOZES et al.

Application No.: 09/187,330

Filed: 11/6/98

For: ACTIVITY DEPENDENT
NEUTROTROPHIC FACTOR III (ADNF
III)

Examiner:

Art Unit: 1643

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. Also enclosed is a copy of the Search/Examination report cited in conjunction with the PCT parent application, international application number PCT/US98/02485. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Annette S. Parent
Reg. No. 42058

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
ASP:pb

4/5/98

| | | | | | | |
|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------------------------------|-----------------|-----------------------------|------------------------------|
| FORM PTO-1449 (Modified) | | | Attorney Docket No.: 15280-2912 | | Application No.: 09/187,330 | |
| LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | Applicant: Gozes et al. | | | |
| | | | Filing Date: 11/6/98 | | Group: 1643 1631 | |
| Reference Designation | | | U.S. PATENT DOCUMENTS | | | Page 1 |
| Examiner Initial | Document No. | Date | Name | Class | Sub-class | Filing Date (If Appropriate) |
| <i>mp</i> AA | 5,767,240 | 06/16/98 | Brenneman et al. | 530 | 350 | |
| FOREIGN PATENT DOCUMENTS | | | | | | |
| | Document No. | Date | Country | Class | Sub-class | Translation (Yes/No) |
| <i>mp</i> AB | WO 92/18140 | 10/29/92 | WIPO | | | |
| AC | WO 96/11948 | 04/25/96 | WIPO | | | |
| AD | WO 98/35042 | 08/13/98 | WIPO | | | |
| OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | |
| AE | Bassan, M. et al. "VIP-Induced Mechanism of Neuroprotection: The Complete Sequence of a Femtomolar-Acting Activity-Dependent Neuroprotective Protein." <i>Regulatory Peptides</i> , Vol. 71, No. 2, August 15, 1997. | | | | | |
| AF | Bassan, M. et al. "Complete Sequence of a Novel Protein Containing a Femtomolar-Activity-Dependent Neuroprotective Peptide." <i>Journal of Neurochemistry</i> , Vol 72, pp. 1283-1293 (1999) | | | | | |
| AG | Beni-Adani, L. et al. "Activity-Dependent Neurotrophic Protein is Neuroprotective in a Mouse Model of Closed Head Injury." Society for Neuroscience, 28 th Annual Meeting, Los Angeles, CA, November 7-12, 1998. <i>Abstracts</i> , Vol. 23, Part 1, p. 1043 (1998). | | | | | |
| AH | Brenneman, D.C. and Gozes, I. "A Femtomolar-Acting Neuroprotective Peptide." <i>Journal of Clinical Investigation</i> , Vol. 97, pp. 229-2307(1996) | | | | | |
| AI | Brenneman, D.E. et al. "Identification of a Nine Amino Acid Core Peptide from Activity Dependent Neurotrophic Factor I." Society for Neuroscience, 27 th Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> , Vol. 23, Part 2, p. 2250 (1997). | | | | | |
| AJ | Brenneman, D.E. et al. "Activity-Dependent neurotrophic Factor: Structure-Activity Relationships of Femtomolar-Acting Peptides." <i>Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 285, pp. 619-627 (1998) | | | | | |
| AK | Davidson, A. et al. "Protection Against Developmental Retardation and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides." Society for Neuroscience, 27 th Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> , Vol. 23, Part 2, p. 2250 (1997). | | | | | |
| AL | Dibbern, D.A., Jr. et al. "Inhibition of Murine Embryonic Growth by Human Immunodeficiency Virus Envelope Protein and Its Prevention by Vasoactive Intestinal Peptide and Activity-Dependent Neurotrophic Factor." <i>Journal of Clinical Investigation</i> , Vol. 99, pp. 28377-2841 (1997) | | | | | |
| AM | Giladi, E. "Protection Against Developmental and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides." <i>Neuroscience Letters</i> , Supplement 48 S1-S60, P. S19 (1997). | | | | | |
| AN | Glazner, G.W. et al. "A 9 Amino Acid Peptide Fragment of Activity-Dependent Neurotrophic Factor (ADNF) Protects Neurons from Oxidative Stress-Induced Death." Society for Neuroscience, 27 th Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> , Vol. 23, Part 2, p. 2249 (1997). | | | | | |
| AO | Gozes, I. et al. "Stearyl-Norleucine-Vasoactive intestinal Peptide (VIP): A novel VIP Analog for Noninvasive Impotence Treatment." <i>Endocrinology</i> , Vol. 134, pp. 2125 (1994). | | | | | |
| AP | Gozes, I. et al. "Superactive Lipophilic Peptides Discriminate Multiple Vasoactive intestinal Peptide Receptors." <i>Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 273, pp. 161-167 (1995). | | | | | |
| AQ | Gozes, I. et al. "Neuroprotective Strategy for Alzheimer Disease: Intranasal Administration of a Fatty Neuropeptide." <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93, pp. 427-432 (1996). | | | | | |
| ✓ AR | Gozes, I. and Brenneman, D.E. "Activity-Dependent Neurotrophic Factor (ADNF)." <i>Journal of Molecular Neuroscience</i> , Vol. 7, pp. 235-244 (1996). | | | | | |
| EXAMINER | | <i>mp</i> | | DATE CONSIDERED | | <i>7/12/00</i> |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| FORM PTO-1449 (Modified) | | Attorney Docket No.: 15280-2912 | | Application No.: 09/187,330 | | |
|---------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|---------|-----------------------------|-----------|------------------------------|
| LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | Applicant: Gozes et al. | | | | |
| | | Filing Date: 11/6/98 | | Group: 1643 /63/ | | |
| Reference Designation | | U.S. PATENT DOCUMENTS | | | | |
| | | Page 2 | | | | |
| Examiner Initial | Document No. | Date | Name | Class | Sub-class | Filing Date (If Appropriate) |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | |
| | Document No. | Date | Country | Class | Sub-class | Translation (Yes/No) |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | |
| <u>MP</u> AS | Gozes, I. et al. "Protection Against Developmental Retardation in Apolipoprotein E-Deficient Mice by a Fatty neuropeptide: Implications for Early Treatment of Alzheimer's Disease." <i>Journal of Neurobiology</i> , Vol. 33, pp. 329-342 (1997). | | | | | |
| AT | Gozes I. et al. "Antiserum to Activity-Dependent Neurotrophic Factor Produces Neuronal Cell Death in CNS Cultures: Immunological and Biological Specificity." <i>Developmental Brain Research</i> , Vol. 99, pp. 167-175 (1997). | | | | | |
| AU | Gozes, I. et al. "The cDNA Structure of a Novel Femtomolar-Acting Neuroprotective Protein: Activity-Dependent-Neurotrophic Factor III (ADNFIII)." Society for Neuroscience, 27 th Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> , Vol. 23, Part 2, p. 2250 (1997). | | | | | |
| AV | Gozes, I. et al. "A Femtomolar-Acting Activity-Dependent Neuroprotective Protein (ADNP). <i>Neuroscience Letters</i> , Supplement 48 S1-S60, p. S21 (1997)- | | | | | |
| AW | Hill, J.M. et al. "Learning Impairment in Adult Mice Produced by Early Embryonic Administration of Antiserum to Activity-Dependent Neurotrophic Factor (ADNF)." Society for Neuroscience, 27 th Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> , Vol. 23, Part 2, p. 2250 (1997). | | | | | |
| AX | Lilling, G. et al. "Inhibition of Human Neuroblastoma Growth by a Specific VIP Antagonist." <i>Journal of Molecular Neuroscience</i> , Vol. 5, pp. 231-239 (1995). | | | | | |
| AY | McKune, S.K. et al. "Localization of mRNA for Activity-Dependent Neurotrophic Factor III (ADNF III) in mouse Embryo and Adult CNS." Society for Neuroscience, 27 th Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> , Vol. 23, Part 2, p. 2249 (1997) | | | | | |
| AZ | Nelbock, P. et al. "A cDNA for a Protein that Interacts with the Human Immunodeficiency Virus Tat Transactivator. <i>Science</i> , Vol. 248, pp. 1650-1653 (1990). | | | | | |
| <u>AAZ</u> | Pelsman, A. et al. "In Vitro Degeneration of Down Syndrome neurons is Prevented by Activity-Dependent Neurotrophic Factor-Derived Peptides." Society for Neuroscience, 28 TH Annual Meeting, Los Angeles, CA, November 7-12, 1998. <i>Abstracts</i> , Vol. 24, p. 1044 (1998) | | | | | |
| EXAMINER <u>MP Allen</u> | | DATE CONSIDERED <u>7/12/00</u> | | | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.